Cancer Care for Leukemias in Russia: Analysis of Prevalence, Mortality, and Survival of Patients with Myeloid (C92), Monocytic (C93), and Other Leukemias (C94-95). Part II

Vakhtang M. Merabishvili; Svetlana A. Kuleva; Larisa V. Filatova; Alexey M. Belyaev; Vladimir V. Perelygin

doi:10.17816/phf678338

Pharmacy Formulas ›› 2025, Vol. 7 ›› Issue (1) :44 -55. DOI: 10.17816/phf678338

Biomedical Sciences

research-article

Cancer Care for Leukemias in Russia: Analysis of Prevalence, Mortality, and Survival of Patients with Myeloid (C92), Monocytic (C93), and Other Leukemias (C94-95). Part II

Author information +

N. N. Petrov National Medical Research Centre of Oncology Ministry of public health of Russian Federation

Saint Petersburg State Pediatric Medical University

North-Western State Medical University named after I. I. Mechnikov

Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health of the Russian Federation

Honored Scientist of the Russian Federation, DSc Med., Professor, Head of the Department of Cancer Statistics

DSc Med., Associate Professor, Leading Researcher at the Scientific Department of Innovative Methods of Therapeutic Oncology and Rehabilitation, Head of the Pediatric Oncology Department, Professor of the Educational and Methodological Department N. N. Petrov National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; Head of the Department of Oncology, Pediatric Oncology and Radiation Therapy at the St. Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation; Chief Freelance Pediatric Oncologist at the Committee on Public

Dr. of Sci. (Med.), Associate Professor, Leading Researcher of the Research Department of Innovative Therapeutic Oncology and Rehabilitation Methods, Oncologist of the Department

Dr. Med. Sci., Professor, Honored Doctor of the Russian Federation, Corresponding Member of RAS, Director of the N. N. Petrov National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation; Head of the Department of Oncology, North-Western State Medical University named after I.I. Mechnikov

Dr. Med. Sci., Professor, Honored Doctor of the Russian Federation, Head of the Industrial Ecology Department

Show less

History +

PDF

Abstract

This work represents the second part of a study dedicated to investigating leukemias in Russia. The focus is on the prevalence, dynamics of histological structure, and annual mortality of myeloid (C92), monocytic (C93), and other leukemias (C94-95), as well as the assessment of patient survival. The analysis confirmed the relatively low prevalence of these diseases and the limited progress in improving treatment outcomes over the past two decades. An important aspect is the use of data from the Population-Based Cancer Registry (PBCR) of the Northwestern Federal District (NWFD), which contains information on over 1.6 million observations, including 28.7 thousand cases of leukemia. This allows us to overcome the limitations associated with the predominance of foreign and clinical data in Russian scientific literature. In addition, the results of the survival analysis of patients with lymphoblastic leukemia (C91), conducted taking into account age, sex, and region of residence (a continuation of the first part of the study), are presented. The aim of the study is to investigate the prevalence of myeloid (C92), monocytic (C93), and other leukemias (C94-95) among the population in Russia, the dynamics of detailed histological structure, and annual mortality. To calculate the survival of patients. The conducted study, with an analysis of the prevalence of myeloid and monocytic leukemias, confirmed the rarity of this pathology and the modest success in the treatment of patients. Over the past two decades, patient mortality has remained virtually unchanged.

Keywords

ICD-10 / Malignant neoplasm / Leukemias / Myeloid leukemia / Monocytic leukemia / Incidence / Patient mortality / Annual mortality / Population-based cancer registry database / International Agency for Research on Cancer (IARC) / Cancer Incidence in Five Continents

Cite this article

Download citation ▾

Vakhtang M. Merabishvili, Svetlana A. Kuleva, Larisa V. Filatova, Alexey M. Belyaev, Vladimir V. Perelygin. Cancer Care for Leukemias in Russia: Analysis of Prevalence, Mortality, and Survival of Patients with Myeloid (C92), Monocytic (C93), and Other Leukemias (C94-95). Part II. Pharmacy Formulas, 2025, 7(1): 44-55 DOI:10.17816/phf678338

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Reference book of comparison of ICD-9 and ICD-10 codes of revisions by class of neoplasms. Second edition updated and expanded / Edited by prof. V. M. Merabishvili. – St. Petersburg, 1997. – 92p. (in Russ).

[2]	Справочник сопоставления кодов МКБ-9 и МКБ-10 пересмотров по классу новообразований. Второе издание уточненное и дополненное / Под ред. проф. В. М. Мерабишвили. – СПб., 1997. – 92с.

[3]	Cancer Incidence in Five Continents. Volume XII. Registry Summary tables. https://ci5.iarc.fr/ci5-xii/tables/summary

[4]	Malignant neoplasms in Russia in 2023 (morbidity and mortality) / Kaprin A. D., Starinsky V. V., Shakhzadova A. O. // Moscow: P. A. Hertsen MNIOI. – 2024. – 276 p. (in Russ).

[5]	Злокачественные новообразования в России в 2023 году (заболеваемость и смертность) / Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. – М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. ИЛЛ –276 с.

[6]	Malignant neoplasms in Russia in 2022 (morbidity and mortality) / Kaprin A. D., Starinsky V. V., Shakhzadova A. O., Lisichnikova I. V. // Moscow: P. A. Hertsen MNIOI. – 2023. – 275 p. (in Russ).

[7]	Злокачественные новообразования в России в 2022 году (заболеваемость и смертность) / Под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой, И. В. Лисичниковой. – М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023. ИЛЛ –275 с.

[8]	Acute Myeloid Leukemia. National Comprehensive Cancer Network (NCCN) Guidelines. 2–2020. [Electronic resource]. URL: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.

[9]	DiNardo C, Lachowiez C. Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions. Curr Hematol Malig Rep. 2019 Oct;14(5):386–394.

[10]

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377.

[11]	Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.

[12]

da Rosa SEA, de Lima LB, Silveira CN, Cortes LGF, de Oliveira Filho JB, de Souza Reis R, Cervato MC, Rodrigues PHS, de Oliveira Pelegrino K, Petroni RC, da Silva Araujo E, Campregher PV. Real-world genomic profiling of acute myeloid leukemia and the impact of European LeukemiaNet risk stratification 2022 update. Clin Transl Oncol. 2023 Dec;25(12):3431–3436.

[13]

Nabergoj M, Eikema DJ, Koster L, Platzbecker U, Sockel K, Finke J, Kröger N, Forcade E, Nagler A, Eder M, Tischer J, Broers AEC, Kuball J, Wilson KMO, Hunault-Berger M, Collin M, Russo D, Corral LL, Helbig G, Mussetti A, Scheid C, Gurnari C, Raj K, Drozd-Sokolowska J, Yakoub-Agha I, Robin M, McLornan DP. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024 Mar;59(3):395–402.

[14]	Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62–70.

[15]	US Food and Drug Administration. 2020, Guidance for industry. Acute myeloid leukemia: developing drugs and biological products for treatment. Available at: https://www.fda.gov/media/140821/. Accessed 30 June 2022.

[16]	Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020; 188(1):129–146.

[17]	Clinical Recommendations “Acute Myeloid Leukemia” approved by the Ministry of Health of Russia. (in Russ).

[18]	Клинические рекомендации «Острые миелоидные лейкозы» утв. Минздравом России [Электронный ресурс]. URL:. https://sudact.ru/law/klinicheskie-rekomendatsii-ostrye-mieloidnye-leikozy-u-vzroslykh/ (дата обращения: 13.03.2025).